Merck's KEYTRUDA (pembrolizumab) Significantly Improves Overall...

Merck's KEYTRUDA (pembrolizumab) Significantly Improves Overall...


Merck's KEYTRUDAA Significantly Improves Overall Survival Compared to Chemotherapy in Previously Treated Patients with Advanced Bladder Cancer First Presentation of Data from Phase 3 KEYNOTE-045 Study Presented at the Society for Immunotherapy of Cancer's 31 st Annual Meeting Merck's KEYTRUDA A Significantly Improves Overall Survival Compared to Chemotherapy in Previously Treated Patients with Advanced Bladder Cancer Merck , known as MSD outside the United States and Canada, today announced results from the pivotal KEYNOTE-045 study investigating the use of KEYTRUDAA , the company's anti-PD-1 therapy, in patients with advanced bladder cancer previously treated with platinum-containing chemotherapy.



from Biotech News